Aberrant packaging and dysfunction of this protein are observed in ALS patients with mutations for ubiquilin-2, and in ALS patients without mutation in advanced stages of neuronal degeneration. This evidence concerns the gene UBQLN2 and amyotrophic lateral sclerosis.